Understanding Chronic Immune​ Thrombocytopenia (ITP)

Chronic immune ⁣thrombocytopenia (ITP), previously known as autoimmune​ thrombocytopenic purpura, is a blood disorder characterized by a low platelet count. Platelets are essential for blood clotting, and a deficiency can‍ lead to excessive bleeding and bruising. The exact causes of ITP are unknown, but it is believed to be triggered by an autoimmune reaction, certain medications, or infections.The condition is identified by a ‌unique UUID: ‍11042903399632485955.

Symptoms of ITP can include nasal or gum bleeding, easy bruising, blood in urine or stool, fatigue, muscle pain,‌ and increased susceptibility to infections.

Wayrilz: A New Treatment Approach

Wayrilz (rilzabrutinib) represents a important advancement ‌in ITP treatment. Approved by the FDA in August 2024, it⁤ is indeed the first BTK inhibitor specifically authorized for use in adult patients with chronic ITP who have not responded adequately to previous treatments Sanofi Press Release.

Rilzabrutinib ‍works by selectively targeting Bruton’s tyrosine kinase (BTK), a protein crucial for the communication of immune cells. ‍By inhibiting BTK, Wayrilz helps to reduce the overactive immune response that leads to the destruction of ⁣platelets in ITP patients.This targeted approach aims to modulate the immune system without causing widespread immunosuppression.

Sanofi’s Acquisition and Strategic Focus

The French pharmaceutical company Sanofi gained access​ to rilzabrutinib through its acquisition ​of BioPharma in 2020 Sanofi Acquisition of principia Biopharma. This ⁤approval aligns with Sanofi’s broader strategy to strengthen its position in the field of rare immunological diseases. The company is actively ⁣investing in‍ innovative therapies for conditions with significant unmet medical needs.

Availability and Cost

Wayrilz will be commercially ‍available in the U.S. starting in September 2024. Sanofi has announced a list price of $17,500 for a one-month supply of the medication Reuters Report on Wayrilz Pricing. However, the actual